Company Overview - Johnson & Johnson's wholly-owned orthopedics company, DePuy Synthes, launched the TriLEAP Lower Extremity Anatomic Plating System, designed for foot and ankle surgeons [1] - The TriLEAP System is part of J&J's strategy to enhance its forefoot and midfoot portfolio, addressing conditions related to the big toe and foot and ankle reconstruction [2] Product Details - The TriLEAP System includes contoured and conventional titanium plates with multiple screw shaft options and color-coded instrumentation for ease of use [2] - It provides a broad range of reconstructive and trauma treatments for adults and adolescents, focusing on fixation and fusing of bones and bone fragments [2] Market Potential - The global orthopedic trauma devices market was valued at $5.9 billion in 2022 and is projected to reach $10.7 billion by 2032, growing at a CAGR of 6.8% [4] - Factors driving market growth include an aging population, increasing prevalence of osteoporosis and musculoskeletal diseases, and a rise in sports and traumatic injuries [4] - The launch of the TriLEAP System is expected to boost DePuy Synthes' business and generate additional revenues [4] Recent Performance - Over the past six months, JNJ's shares have increased by 2.2%, while the industry has grown by 3.9% and the S&P 500 has also risen by 3.9% [5]

These longtime winners still have a lot to offer.The healthcare sector is home to many prominent corporations. Few are more famous or recognizable than Eli Lilly (LLY 9.48%) and Johnson & Johnson (JNJ 0.83%), both of which are among the largest companies in the industry. These two leaders have been at it for decades, delivering important innovations, posting consistent financial records, and rewarding long-term shareholders.However, it isn't too late to invest in Eli Lilly or Johnson & Johnson: These compan ...

Nipocalimab delayed or prevented severe fetal anemia and 54 percent of study participants in the Phase 2 UNITY study achieved a live birth at or after 32 weeks without the need for intrauterine transfusion (IUT)The AZALEA Phase 3 clinical study is currently enrolling patients: Nipocalimab is the only therapy in clinical development for use in pregnancies at risk for severe hemolytic disease of the fetus and newborn (HDFN) SPRING HOUSE, Pa., Aug. 7, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today an ...

Johnson & Johnson (JNJ) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Over the past month, shares of this world's biggest maker of health care products have returned +8.1%, compared to the Zacks S&P 500 composite's -5.9% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Johnson & Johnson falls in, has lost 3.9%. The key question now is: What could ...

Dividend-paying stocks are ideal for outperforming the market or generating passive income. Finding dividend growth stocks, companies that have shown the ability and willingness to raise their distributions over time, providing consistent and growing income to investors, are even more valuable, particularly in this current market.Many investors seek stability over growth as a rotation builds in the broader market. There’s historical precedence for such a view. From 1973 to 2023, S&P 500 non-dividend stocks ...

The most recent U.S. jobs report published on Friday, August 2, gave investors a fright, as evidenced by the massive bloodbath in both the stock market and across the cryptocurrency markets, with the flagship digital asset Bitcoin (BTC) now struggling to stay above $50,000.The report, which showed that 114,000 jobs have been created in July instead of the predicted 175,000, has also reignited fears of a coming recession – partially driven by FED’s high interest rates – and is, judging by the extended tradin ...

Findings from first-ever quadruplet therapy study with subcutaneous DARZALEX FASPRO® showed 60 percent reduction in risk of disease progression or deathNew regimen solidifies DARZALEX FASPRO® as a foundational frontline therapy in multiple myeloma with potential to significantly delay disease progressionHORSHAM, Pa., July 30, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in com ...

As the second half of the year has gotten underway, the healthcare sector, represented by the XLV ETF, has seen a notable resurgence. This sector, which had been underperforming since the pandemic, is now breaking out of a multi-year consolidation phase. In July alone, the XLV ETF surged almost 3%, while the overall market, as represented by the SPY, declined by 0.2%. This rotation of capital into healthcare highlights a renewed interest in the sector, which has primarily lagged in recent years.Get Pfizer a ...

Is it safe to buy Johnson & Johnson stock now?One of the biggest risks facing Johnson & Johnson (JNJ 0.63%) in recent years has been its exposure to talc lawsuits. The uncertainty around that issue is a key reason why shares of Johnson & Johnson have declined by 9% in the past three years, with the legal cloud weighing heavily on the business.While the company has set aside billions of dollars to account for lawsuits that allege talc-based products led to people developing cancer, Johnson & Johnson has fail ...

If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive PAH portfolio has the potential to cover all guideline-recommended treatment pathways BEERSE, BELGIUM, July 26, 2024 (GLOBE NEWSWIRE) --  Janssen-Cilag International NV, a Johnson & Johnson company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the Marketing Authorisation (MA) of Yu ...